Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. March 21, 2018. Jason Bhan.

Executive Summary

Start-up firm Prognos has a lofty long-term mission: to use artificial intelligence and other smart technologies to eradicate disease. Check out what company cofounder Jason Bhan had to say about Prognos' use of AI here.

"Our vision is to use the data and the product and the capabilities we have to eradicate disease. In the interim – over the next five years – we will figure out how to predict where disease is going to occur and enable others to intervene at those points, so we can help people get diagnosed and then treated faster." –Jason Bhan, cofounder and chief medical officer, Prognos

Find out more: Start-Up Spotlight: Payers, Pharma Clients Bank On Prognos' Artificial Intelligence To Predict Disease

Click here for a free trial of Medtech Insight

Advertisement

Related Content

Start-Up Spotlight: Payers, Pharma Clients Bank On Prognos' Artificial Intelligence To Predict Disease

Topics

Advertisement
UsernamePublicRestriction

Register

MT122366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel